行情回顾: A 股医药生物指数上涨2.67%,跑赢沪深300 指数1.03pp,跑输创业板综指2.00pp,在31 个子行业中排名第17。H 股恒生医疗健康指数上周上涨3.85%,跑赢恒生国企指数1.49pp。研发进展:上周,德琪医药的ATG-022、歌礼制药的CH006、复星医药的FXS887的IND 申请新进承办;沃森生物的带状疱疹mRNA 疫苗的临床申请新进承办。本周观点:关注血液净化器械...
Source Link行情回顾: A 股医药生物指数上涨2.67%,跑赢沪深300 指数1.03pp,跑输创业板综指2.00pp,在31 个子行业中排名第17。H 股恒生医疗健康指数上周上涨3.85%,跑赢恒生国企指数1.49pp。研发进展:上周,德琪医药的ATG-022、歌礼制药的CH006、复星医药的FXS887的IND 申请新进承办;沃森生物的带状疱疹mRNA 疫苗的临床申请新进承办。本周观点:关注血液净化器械...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.